Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
31 studies found for:    "Diffuse systemic sclerosis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Conditions: Scleroderma, Diffuse;   Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: IVA337;   Drug: Placebo
2 Completed Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
Condition: Early Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Methotrexate;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
3 Recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
4 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
5 Unknown † Serial Night Time Position Splint on Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Interventions: Device: Serial night time position splint;   Drug: Drug treatment
6 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
7 Active, not recruiting Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: JBT-101;   Drug: Placebo
8 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo
9 Active, not recruiting Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan
10 Unknown † High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
11 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
12 Active, not recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
13 Recruiting Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers and Patients With Cutaneous Scleroderma
Conditions: Limited Scleroderma;   Localized Scleroderma;   Diffuse Scleroderma
Interventions: Drug: MRG-201;   Drug: Placebo
14 Completed A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Conditions: Limited Scleroderma;   Diffuse Scleroderma
Intervention:
15 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
16 Unknown † AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
17 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
18 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
19 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
20 Recruiting Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study
Condition: Autoimmune Diseases
Intervention: Procedure: Autologous HSCT
To Top

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
† Indicates status has not been verified in more than two years